お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
769586

カンナビジオール (CBD) 治療薬:機会の評価・市場ダイナミクス・パイプライン分析

Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H2 2018

出版日: | 発行: GervanoRA Data Services LLP | ページ情報: 英文 200 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.77円
カンナビジオール (CBD) 治療薬:機会の評価・市場ダイナミクス・パイプライン分析
出版日: 2019年01月26日
発行: GervanoRA Data Services LLP
ページ情報: 英文 200 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

当レポートでは、世界のカンナビジオール (CBD) 治療薬市場について調査し、市場の概要、市場ダイナミクス、パイプライン治療薬の承認スケジュール予測、現在・将来の競合情勢、主要企業のプロファイル、新興企業のプロファイル、パイプライン治療薬の説明と開発におけるマイルストーンなどについて分析しています。

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 カンナビノイド治療薬の概要

  • 大麻の展望
  • 世界の大麻製品の概要

第4章 市場ダイナミクス

  • 政府の規制ダイナミクス・影響
  • 契約
  • 新薬の承認 (EMA)
  • 新薬の承認 (USFDA)
  • 特許分析 (失効・ジェネリック医薬品)

第5章 パイプライン分析・承認スケジュールの予測

  • パイプライン分析:開発段階別
  • パイプライン分析:地域別
  • パイプライン分析:投与経路別
  • パイプライン分析:薬剤クラス別
  • パイプライン分析:作用機序別
  • パイプライン分析:適応症別
  • パイプライン分子の分析:原料別 (植物由来 vs. 合成)
  • パイプライン分子の分析:タイプ別 (カンナビジオール (CBD) vs. テトラヒドロカンナビノール (THC))
  • 承認スケジュールの予測

第6章 カンナビノイドの機会:アプリケーション領域別

  • 医薬品産業
  • 食品産業
  • 化粧品産業

第7章 現在・将来の競合情勢

  • 企業
  • 大学・機関

第8章 略語

目次
Product Code: GERPH223

GervanoRA's pipeline analysis and opportunity assessment report "Cannabidiol (CBD) Drugs: Pipeline Analysis and Opportunity Assessment, H2 2018" analyzed and assessed Cannabidiol pipeline molecules for the opportunities in the competitive space by covering all the pipeline molecules in different stages of development and all the companies which are actively involved in Cannabidiol Drugs industry. To provide systematic pipeline analytics, we have segregated total pipeline molecules into different segments like Pipeline Molecules by Geography, Pipeline Molecules by Drug Class, Pipeline Molecules by Mechanism of Action and Pipeline Molecules by Stage of development.

Report is more focused to provide competitive opportunities by assessing and providing in-depth analytics on:

  • Unmet needs and Opportunities
  • Epidemiology and Epidemiology forecast 2019 - 2025
  • Market Dynamics with Coverage of Deals (Mergers, Acquisitions, Partnering, Collaborations etc.)
  • Patent Analysis of Pipeline Molecules
  • Pipeline Analysis and Estimated Pipeline Drug Approval Time lines
  • Clinical Trials Summary
  • Current and Future Competitive Landscape
  • Key Company Profiles with SWOT Analysis
  • Emerging Company Profiles with Opportunity Assessments
  • Pipeline Drug Descriptions along with Development milestones (Past and Future)
  • University Pipeline Molecules & In-Licensing/Out Licensing Opportunities

Report helps clients to refine the commercial opportunities from the existing treatment armamentarium to pipeline assets, deals, and deal comparables. Even it helps in identifying the most relevant actors in the field for partnering deals.

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. METHODOLOGY
  • 1.3. UPCOMING AND OTHER AVAILABLE PIPELINE ANALYSIS REPORTS
  • 1.4. ABOUT US: GERVANORA DATA SERVICES

2. EXECUTIVE SUMMARY

  • 2.1. REPORT SUMMARY
  • 2.2. KEY EVENTS IN CANNABINOIDS COMPETITIVE SPACE
  • 2.3. KEY MAJOR FINDINGS
    • 2.3.1. DRIVERS
    • 2.3.2. RESTRAINTS
    • 2.3.3. UNMET NEEDS AND OPPORTUNITIES

3. CANNABINOIDS DRUGS OVERVIEW

  • 3.1. CANNABIS OUTLOOK
  • 3.2. GLOBAL CANNABIS PRODUCT OUTLINE

4. MARKET DYNAMICS

  • 4.1. GOVERNMENT REGULATORY DYNAMICS AND IMPACT
  • 4.2. DEALS (MERGERS/ ACQUISITIONS / COLLABORATIONS)
    • 4.2.1. ACQUISITIONS
    • 4.2.2. COLLABORATION AGREEMENTS
    • 4.2.3. LICENSING AGREEMENTS
    • 4.2.4. TERMINATION AGREEMENTS AND SETTLEMENTS
    • 4.2.5. PARTNERSHIPS
    • 4.2.6. AGREEMENTS
  • 4.3. NEW DRUG APPROVALS (EMA)
  • 4.4. NEW DRUG APPROVALS (USFDA)
  • 4.5. PATENT ANALYSIS (EXPIRES AND GENERICIZATION)

5. PIPELINE ANALYSIS AND ESTIMATED APPROVAL TIMELINE

  • 5.1. PIPELINE ANALYSIS BY STAGE OF DEVELOPMENT
    • 5.1.1. PRE-REGISTRATION (FILED) MOLECULES
    • 5.1.2. PHASE 3 MOLECULES
    • 5.1.3. PHASE 2 MOLECULES
    • 5.1.4. PHASE 1 MOLECULES
    • 5.1.5. PRECLINICAL MOLECULES
    • 5.1.6. EARLY R&D MOLECULES
    • 5.1.7. HSD-UNKNOWN
  • 5.2. PIPELINE ANALYSIS BY GEOGRAPHY
    • 5.2.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.3. PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
    • 5.3.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.4. PIPELINE ANALYSIS BY DRUG CLASS
    • 5.4.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.5. PIPELINE ANALYSIS BY MECHANISM OF ACTION
  • 5.6. PIPELINE ANALYSIS BY INDICATION
    • 5.6.1. UNMET NEEDS AND OPPORTUNITIES
  • 5.7. ANALYTICS ON PIPELINE MOLECULES BY SOURCE OF ORIGIN (PLANT DERIVED VERSUS SYNTHETIC ANALYTICS)
  • 5.8. ANALYTICS ON PIPELINE MOLECULES BY TYPE (CANNABIDIOL - CBD VS TETRAHYDROCANNABINOL -THC)
  • 5.9. ESTIMATED APPROVAL TIMELINES
    • 5.9.1. METHODOLOGY
    • 5.9.2. ESTIMATED APPROVAL TIMELINES US & EX-US

6. CANNABINOIDS OPPORTUNITIES BY AREA OF APPLICATION

  • 6.1. PHARMACEUTICAL INDUSTRY
    • 6.1.1. UNMET NEEDS AND OPPORTUNITIES
    • 6.1.2. EXPECTED MARKET IN 11MM
  • 6.2. FOOD INDUSTRY
    • 6.2.1. UNMET NEEDS AND OPPORTUNITIES
    • 6.2.2. EXPECTED MARKET IN 11MM
  • 6.3. COSMETIC INDUSTRY
    • 6.3.1. UNMET NEEDS AND OPPORTUNITIES
    • 6.3.2. EXPECTED MARKET IN 11MM

7. CURRENT AND FUTURE COMPETITIVE LANDSCAPE

  • 7.1. COMPANIES
    • 7.1.1. ESTABLISHED COMPANY PROFILES WITH SWOT ANALYSIS
      • 7.1.1.1. GW RESEARCH LTD
      • 7.1.1.2. ABBVIE INC
      • 7.1.1.3. INSYS THERAPEUTICS
      • 7.1.1.4. MYLAN PHARMA
      • 7.1.1.5. TILRAY
      • 7.1.1.6. CANOPY GROWTH
      • 7.1.1.7. AURORA CANNABIS
      • 7.1.1.8. GREEN THUMB INDUSTRIES
      • 7.1.1.9. CRONOS GROUP
    • 7.1.2. EMERGING COMPANIES WITH COMPETITIVE OPPORTUNITIES
      • 7.1.2.1. KALYTERA THERAPEUTICS
      • 7.1.2.2. BOTANIX PHARMACEUTICALS
      • 7.1.2.3. PHYTECS
      • 7.1.2.4. CV SCIENCES, INC
      • 7.1.2.5. SERINA THERAPEUTICS, INC
      • 7.1.2.6. INTEC PHARMA LTD
      • 7.1.2.7. AXIM BIOTECHNOLOGIES
      • 7.1.2.8. INMED PHARMACEUTICALS INC
      • 7.1.2.9. CARA THERAPEUTICS (COVERED CANNABINOID RELATED INFORMATION ONLY)
      • 7.1.2.10. VIVACELL BIOTECHNOLOGY ESPANA SL
      • 7.1.2.11. CARDIOL THERAPEUTICS INC
      • 7.1.2.12. PIVOT PHARMACEUTICALS
      • 7.1.2.13. ARTELO BIOSCIENCES
      • 7.1.2.14. TETRA BIO-PHARMA
      • 7.1.2.15. NEMUS BIOSCIENCE INC
      • 7.1.2.16. SCYTHIAN BIOSCIENCES
      • 7.1.2.17. ICD PHARMA
      • 7.1.2.18. CANADIAN CANNABIS MEDICAL TECHNOLOGIES
      • 7.1.2.19. ZYNERBA PHARMACEUTICALS
      • 7.1.2.20. THERAPIX BIOSCIENCES
      • 7.1.2.21. REVIVE THERAPEUTICS
      • 7.1.2.22. PANAG PHARMA
      • 7.1.2.23. ZELDA THERAPEUTICS PTY LTD
  • 7.2. UNIVERSITIES AND INSTITUTES

8. ABBREVIATIONS

LIST OF TABLES

  • TABLE 1: ECS STIMULATION ON DIFFERENT PARTS OF THE BODY
  • TABLE 2: AMOUNT SPENT ON MARIJUANA REASERCH, 2014-2017, US, IN $M
  • TABLE 3: MAJOR COLLABORATIVE AGREEMENTS INVOLVING CANNABINOID
  • TABLE 4: MAJOR LICENSING AGREEMENTS INVOLVING CANNABINOID
  • TABLE 5: MAJOR PARTNERSHIPS INVOLVING CANNABINOID
  • TABLE 6: MAJOR AGREEMENTS INVOLVING CANNABINOID
  • TABLE 7: EMA APPROVED CANNABIS DRUGS
  • TABLE 8: US FDA APPROVED CANNABIS DRUGS
  • TABLE 9: PHASE 3 MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 10: PHASE 2 MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 11: PHASE 1 MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 12: PRECLINICAL MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 13: EARLY R&D MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 14: HSD-UNKNOWN MOLECULES IN THE CANNABINOID DRUG PIPELINE
  • TABLE 15: CANNABINOID DRUG PIPELINE MOLECULES BY ORAL AS ROUTE OF ADMINISTRATION
  • TABLE 16: CANNABINOID DRUG PIPELINE MOLECULES BY TOPICAL AS ROUTE OF ADMINISTRATION
  • TABLE17: CANNABINOID DRUG PIPELINE MOLECULES BY INTRAVENOUS AS ROUTE OF ADMINISTRATION
  • TABLE 18: CANNABIDIOL DRUG PIPELINE MOLECULES BY TRANSDERMAL AS ROUTE OF ADMINISTRATION
  • TABLE 19: OTHER DIFFERENT ROUTE OF ADMINISTRATION FOR CANNABINOID DRUG PIPELINE
  • TABLE 20: CANNABINOID DRUG PIPELINE INDICATED FOR CANCER
  • TABLE 21: CANNABINOID DRUG PIPELINE INDICATED FOR CARDIOVASCULAR, METABOLICS & HEMATOLOGY
  • TABLE 22: CANNABINOIDDRUG PIPELINE INDICATED FOR CENTRAL NERVOUS SYSTEM
  • TABLE 23: CANNABINOID DRUG PIPELINE INDICATED FOR DERMATOLOGY
  • TABLE 24: CANNABINOID DRUG PIPELINE INDICATED FOR ENT & OPHTHALMOLOGY MARKET
  • TABLE 25: CANNABINOIDDRUG PIPELINE INDICATED FOR GASTROINTESTINAL MARKET
  • TABLE 26: CANNABINOID DRUG PIPELINE INDICATED FOR GENETIC AND RARE DISEASE MARKET
  • TABLE 27: CANNABINOID DRUG PIPELINE INDICATED FOR IMMUNOLOGY & INFLAMMATORY MARKET
  • TABLE 28: CANNABINOID DRUG PIPELINE INDICATED FOR INFECTIOUS DISEASE MARKET
  • TABLE 29: CANNABINOID DRUG PIPELINE INDICATED FOR RESPIRATORY MARKET
  • TABLE 30: CANNABINOID DRUG PIPELINE MOLECULES IN OTHER MARKET
  • TABLE 31: COMPANIES DEVELOPING PLANT DERIVED MOLECULES
  • TABLE 32: COMPANIES DEVELOPING SYNTHETIC MOLECULES
  • TABLE 33: COMPANIES DEVELOPING BIOSYNTHETIC MOLECULES
  • TABLE 34: COMPANIES DEVELOPING CBD MOLECULES
  • TABLE 35: COMPANIES DEVELOPING THC MOLECULES
  • TABLE 36: COMPANIES DEVELOPING CBD AND THC MOLECULES
  • TABLE 37: ESTIMATED APPROVAL TIMELINES OF PIPELINE MOLECULES
  • TABLE 38: GW RESEARCH PRODUCT PORTFOLIO
  • TABLE 39: R&D ACTIVITIES OF GW RESEARCH
  • TABLE 40: CONFERENCES/SEMINARS ATTENDED BY GW RESEARCH
  • TABLE 41: RECENT DEVELOPMENTS MADE BY GW RESEARCH
  • TABLE 42: SWOT ANALYSIS OF GW RESEARCH
  • TABLE 43: ABBVIE PRODUCT PORTFOLIO
  • TABLE 44: CONFERENCES/SEMINARS ATTENDED BY ABBVIE
  • TABLE 45: RECENT DEVELOPMENTS MADE BY ABBVIE
  • TABLE 46: SWOT ANALYSIS OF ABBVIE
  • TABLE 47: INSYS THERAPEUTICS PRODUCT PORTFOLIO
  • TABLE 48: R&D ACTIVITIES OF INSYS THERAPEUTICS
  • TABLE 49: CONFERENCES/SEMINARS ATTENDED BY INSYS THERAPEUTICS
  • TABLE 50: RECENT DEVELOPMENTS MADE BY INSYS THERAPEUTICS
  • TABLE 51: SWOT ANALYSIS OF INSYS THERAPEUTICS
  • TABLE 52: MYLAN PHARMA PRODUCT PORTFOLIO
  • TABLE 53: MYLAN PHARMA PRODUCT PIPELINE
  • TABLE 54: CONFERENCES/SEMINARS ATTENDED BY MYLAN PHARMA
  • TABLE 55: RECENT DEVELOPMENTS MADE BY MYLAN PHARMA
  • TABLE 56: SWOT ANALYSIS OF MYLAN PHARMA
  • TABLE 57: TILRAY PRODUCT PORTFOLIO
  • TABLE 58: CONFERENCES/SEMINARS ATTENDED BY TILRAY
  • TABLE 59: RECENT DEVELOPMENTS MADE BY TILRAY
  • TABLE 60: SWOT ANALYSIS OF TILRAY
  • TABLE 61: CANOPY GROWTH PRODUCT PORTFOLIO
  • TABLE 62: RECENT DEVELOPMENTS MADE BY CANOPY GROWTH
  • TABLE 63: SWOT ANALYSIS OF CANOPY GROWTH
  • TABLE 64: AURORA CANNABIS PRODUCT PORTFOLIO
  • TABLE 65: R&D ACTIVITIES OF AURORA CANNABIS
  • TABLE 66: RECENT DEVELOPMENTS MADE BY AURORA CANNABIS
  • TABLE 67: SWOT ANALYSIS OF AURORA CANNABIS
  • TABLE 68: GREEN THUMB INDUSTRIES PRODUCT PORTFOLIO
  • TABLE 69: CONFERENCES/SEMINARS ATTENDED BY GREEN THUMB INDUSTRIES
  • TABLE 70: RECENT DEVELOPMENTS MADE BY GREEN THUMB INDUSTRIES
  • TABLE 71: SWOT ANALYSIS OF GREEN THUMB INDUSTRIES
  • TABLE 72: CRONOS GROUP PRODUCT PORTFOLIO
  • TABLE 73: R&D ACTIVITIES OF CRONOS GROUP
  • TABLE 74: SWOT ANALYSIS OF CRONOS GROUP
  • TABLE 75: KALYTERA THERAPEUTICS FUTURE MILESTONES
  • TABLE 76: KALYTERA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 77: BOTANIX PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 78: PHYTECS PRODUCT PORTFOLIO
  • TABLE 79: PHYTECS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 80: CV SCIENCES FUTURE MILESTONES
  • TABLE 81: CV SCIENCES RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 82: SERINA THERAPEUTICSRECENT DEVELOPMENTS AND MILESTONES
  • TABLE 83: INTEC PHARMA FUTURE MILESTONES
  • TABLE 84: INTEC PHARMA RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 85: AXIM BIOTECHNOLOGIES RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 86: INMED PHARMACEUTICALS FUTURE MILESTONES
  • TABLE 87: INMED PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 88: VIVACELL BIOTECHNOLOGY RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 89: CARDIOL THERAPEUTICS FUTURE MILESTONES
  • TABLE 90: CARDIOL THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 91: ARTELO BIOSCIENCES PRODUCT PORTFOLIO
  • TABLE 92: RECENT DEVELOPMENTS AND FUTURE MILESTONES OF ARTELO BIOSCIENCES
  • TABLE 93: TETRA BIO-PHARMA FUTURE MILESTONES
  • TABLE 94: TETRA BIO-PHARMA RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 95: NEMUS BIOSCIENCE RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 96: ZYNERBA PHARMACEUTICALS FUTURE MILESTONES
  • TABLE 97: ZYNERBA PHARMACEUTICALS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 98: ZELDA THERAPEUTICS FUTURE MILESTONES
  • TABLE 99: ZELDA THERAPEUTICS RECENT DEVELOPMENTS AND MILESTONES
  • TABLE 100: UNIVERSITIES AND INSTITUTES CONDUCTING RESEARCH ON CANNABINOIDS

LIST OF FIGURES

  • FIGURE 1: KEY PIPELINE EVENTS, 2019-2032
  • FIGURE 2: KEY PIPELINE EVENTS, 2019-2021
  • FIGURE 3: PHARMACODYNAMIC EFFECTS OF KEY CANNABINOIDS
  • FIGURE 4: OVERALL DEALS ACTIVITY INVOLVING CANNABINOID
  • FIGURE 5: GEOGRAPHY WISE BREAK UP V/S DEAL TYPE
  • FIGURE 6: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT
  • FIGURE 7: CANNABINOID DRUG PIPELINE ANALYSIS BY GEOGRAPHY
  • FIGURE 8: CANNABINOID DRUG PIPELINE ANALYSIS BY STAGES OF DEVELOPMENT V/S GEOGRAPHIES
  • FIGURE 9: CANNABINOID DRUG PIPELINE ANALYSIS BY ROUTE OF ADMINISTRATION
  • FIGURE 10: CANNABINOID DRUG PIPELINE ANALYSIS BY INDICATION
  • FIGURE 11: GRAPHICAL VIEW OF PIPELINE MOLECULE'S STAGE OF DEVELOPMENT VS SOURCE OF ORIGIN
  • FIGURE 12: GRAPHICAL VIEW OF PIPELINE MOLECULE'S GEOGRAPHY VS SOURCE OF ORIGIN
  • FIGURE 13: PIPELINE MOLECULE'S ANALYTICS BY TYPE (CBD VS THC)
  • FIGURE 14: GRAPHICAL VIEW OF PIPELINE MOLECULE'S STAGE OF DEVELOPMENT VS MOLECULE TYPE
  • FIGURE 15: GRAPHICAL VIEW OF PIPELINE MOLECULE'S GEOGRAPHY VS MOLECULE TYPE
  • FIGURE 16: CANNABINOID OPPORTUNITY ASSESSMENT
  • FIGURE 17: TOTAL CANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 18: PHARMACEUTICAL INDUSTRY CANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 19: FOOD INDUSTRYCANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 20: COSMETIC INDUSTRYCANNABINOID MARKET, 2016 V/S 2025
  • FIGURE 21: FINANCIAL INFORMATION OF GW RESEARCH
  • FIGURE 22: FINANCIAL INFORMATION OF ABBVIE
  • FIGURE 23: FINANCIAL INFORMATION OF INSYS THERAPEUTICS
  • FIGURE 24: FINANCIAL INFORMATION OF MYLAN PHARMA
  • FIGURE 25: FINANCIAL INFORMATION OF TILRAY
  • FIGURE 26: FINANCIAL INFORMATION OF CANOPY GROWTH
  • FIGURE 27: FINANCIAL INFORMATION OF AURORA CANNABIS
  • FIGURE 28: FINANCIAL INFORMATION OF GREEN THUMB INDUSTRIES
  • FIGURE 29: FINANCIAL INFORMATION OF CRONOS GROUP
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.